• Enveric Biosciences reported positive preclinical phototoxicity results for its lead neuroplastogen candidate EB-003; the results have already been presented.
• The analysis found no photoreactive potential, supporting a favorable safety profile and reducing development risk for chronic use in neuropsychiatric disorders.
• The outcome supports plans to move EB-003 into first-in-human Phase 1 clinical trials.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Enveric Biosciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202605190800BIZWIRE_USPR_____20260519_BW940575) on May 19, 2026, and is solely responsible for the information contained therein.